Share |

Novel Therapeutic Targets in Rheumatoid Arthritis

Review article




Rheumatoid arthritis (RA) is the most common chronic systemic autoimmune  disease worldwide. Although incurable, there are available therapies to effectively  control the disease activity and minimize the joint damage. Numerous cytokines, enzymes and other forms of proteins have been implicated in the disease process of RA. In general, pharmacological therapies in RA target cytokine pathways. Despite a wide variety of disease modifying antirheumatic drugs (DMARD), a significant  proportion of patients remain refractory to the available therapies. Hence, the  search for newer drugs with different modes of actions is an ongoing process. The present review aimed to explore novel therapeutic targets in RA based on data  from the literature. Inhibitors of spleen tyrosine kinase, choline kinase, galectin 3  and hypoxia-inducible factor may have a promising role in the treatment of RA.  Besides, cell based therapies which may enhance the levels of systemic  tristetraprolin could be beneficial in RA.